SWOT Analysis for Keros Therapeutics Inc - Weakness

Add SWOT widget to your site/app

Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV

Companies with 10% increase in share price over three months, with rising net profit growth

Relative Outperformance versus Industry over 1 Week

Significant (over 30%) distance from 52 week high

Rising Net Cash Flow and Cash from Operating activity

Relative Outperformance versus Industry over the Quarter (3 Months)

Turnaround Companies: Loss to Profit QoQ

Good quarterly growth in the recent results

Relative Outperformance versus Industry over 1 Week

Companies with Low Debt

Increasing Revenue every quarter for the past 3 quarters

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Recent Results : Growth in Operating Profit with increase in operating margins (YoY)

Increasing profits every quarter for the past 2 quarters

Volume Shockers

Stocks Outperforming their Industry Price Change in the Quarter

PE higher than Industry PE

PEG greater than Industry PEG

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

High PE (PE > 40)

Lowest Momentum Scores (Technical Scores)

Oversold by Money Flow Index (MFI)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Slowing Down Stocks (DVM)

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Highest fall from 52 Week High

High volume, top losers

Top Losers

Low Piotroski Score : Companies with weak financials

Annual net profit declining for last 2 years

RSI indicating price weakness

Top Losers

Mutual Funds Increased Shareholding in Past Month

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Mf buying for 2 months

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks